Bristol Myers Squibb (BMS) will consolidate its research and development operations into a single organization under the leadership of current Chief Medical Officer and Head of Development Cristian Massacesi, M.D., effective January 1, 2027. The restructuring will bring the company’s scientific research and clinical development functions together, while Chief Research Officer Robert Plenge, M.D., Ph.D., will leave the company in March 2027 following the transition.
Massacesi will lead the newly combined R&D organization as its head. Plenge, who currently serves as chief research officer, will continue in an advisory capacity until his departure in March. The company has not clarified whether the organizational changes will affect employees beyond the two executives involved in the leadership transition.
BMS Seeks Greater Integration Across R&D
The restructuring is intended to bring scientific and clinical expertise together within the company’s research and development operations. BMS Chief Executive Officer Christopher Boerner said the decision reflects the increasingly connected nature of research and development activities.
“Increasingly, traditional boundaries between research and development are collapsing,” Boerner said in a statement.
He explained that combining the two functions would position the company to attract and retain talent, develop important capabilities and integrate new technologies. Boerner also said the revised structure would connect scientific and clinical expertise more closely, accelerate decision-making and improve the execution of the company’s development portfolio.
The organizational changes follow Boerner’s stated intention to improve the productivity and efficiency of BMS’ R&D operations. During the company’s third-quarter earnings call in October, he told analysts that BMS was continuing to change how it operates, with an emphasis on making research and development activities faster and more efficient. He identified the company’s organizational structure as one of the areas in which it would pursue greater productivity and efficiency.
Potential Workforce Implications Remain Unclear
BMS has not provided details about whether the restructuring will result in changes to positions beyond the leadership transition involving Massacesi and Plenge.
The company’s research and development operations employed approximately 8,000 people in 2023. Its overall workforce subsequently declined from approximately 34,100 employees at the end of 2023 to 32,500 by the end of 2025.
BMS maintains a substantial research and development presence in the United States, with key facilities in California, Massachusetts and New Jersey. The company has been approached for further information about the potential wider implications of the restructuring.
Reversal of Post-Celgene Organizational Structure
The decision also changes the organizational arrangement BMS introduced following its 2019 acquisition of Celgene.
Before the acquisition, Thomas Lynch, M.D., served as the company’s chief scientific officer and oversaw research and development. Following the transaction, BMS divided responsibilities between two leadership positions. Rupert Vessey was assigned oversight of research and early development, while Samit Hirawat, M.D., was placed in charge of global drug development.
The new arrangement brings both functions back under a single leadership structure, aligning BMS with several other major US pharmaceutical companies. Eli Lilly, Merck & Co. and Pfizer are among the drugmakers whose leaders oversee research and development within one division.
The restructuring comes as analysts are closely watching BMS‘ drug development pipeline for indications of the company’s growth. Massacesi will assume leadership of the combined organization on January 1, 2027, while Plenge is scheduled to leave the company in March.
BMS Creates a Unified Research and Development Organization
The restructuring will bring scientific research and clinical development under one organizational structure. Previously, these functions operated through separate leadership arrangements, creating distinct responsibilities across early research and later-stage development.
Under the new model, BMS intends to connect scientific discoveries more closely with clinical research activities. This could help teams evaluate promising drug candidates, identify development challenges earlier and make decisions with a broader understanding of scientific and clinical priorities.
The unified organization will cover activities ranging from early-stage discovery to clinical development.
According to the company, the restructuring is designed to improve collaboration, strengthen portfolio execution and help translate scientific discoveries into medicines more efficiently.


